RARA and breast cancer: With minimal toxicity both in vitro and in vivo, novel RXR family members (rexinoids), have been reported to suppress breast cancer development in several animal models and have been extensively evaluated either alone or in combination with selective ER modulators.18 One RXRG partner, RARA was shown to influence the ERα transcriptional complex in oestrogen-treated MCF-7 breast cancer cells.19,20 Altogether, these findings indicate that RXRG could have a function in tumour pathogenesis and could potentially be promising cancer therapeutics.